期刊文献+

造血干细胞移植受者环孢素A血药浓度监测指标研究 被引量:4

Monitoring Indexes of Plasma CsA Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation
原文传递
导出
摘要 目的:探讨造血干细胞移植受者环孢素A(CsA)理想的血药浓度监测指标。方法:采用荧光偏振免疫(FPIA)法,对23例造血干细胞移植受者进行全血中CsA谷浓度(C0)及服药后2h血药浓度(C2)进行监测,并对数据进行归纳分析。结果:造血干细胞移植术后6月内C0平均值为(228·84±142·48)μg·L-1,C2平均值为(741·50±294·42)μg·L-1,C0+C2平均值为(970·34±391·18)μg·L-1,C2/C0平均值为(3·88±1·94)μg·L-1。结论:C0+C2和C2/C0作为CsA血药浓度监测指标合理,更能全面反映CsA体内药物暴露情况,并能监测CsA肝、肾毒性。 OBJECTIVE: To study the optimal monitoring indexes of plasma concentration of cyclosporine A (CsA) in patients receiving hematopoietic stem cell transplantation. METHODS: The lowest CsA concentration (C0) and the highest CsA concentration (C2) in 23 hematopoietic stem cell transplant recipients were detected by FPIA. All the data were analyzed statistically. RESULTS: Within 6 months after hematopoietic stem cell transplanttion, C0, C2, C0+ C2 and C2/C0 in the recipients were (228.84±142.48) μg·L^-1, (741.50±294.42) μg·L^-1, (970.34±391.18) μg·L^-1 and (3.88±1.94) μg·L^-1, respectively. CONCLUSION : As reasonable monitoring indexes for the plasma concentration of CsA, C0+ C2 and C2/C0 can comprehensively reflect the exposure of drug in body and monitor the toxicity of CsA in liver and kidney.
出处 《中国药房》 CAS CSCD 北大核心 2008年第8期584-586,共3页 China Pharmacy
基金 南京市医学科技发展项目(ykk05086)
关键词 造血干细胞移植 环孢素A 血药浓度 监测指标 荧光偏振免疫法 Hematopoietic stem cell transplant Cyclosporine A Blood drug concentration Monitoring index Fluorescence polarization immunoassay
作者简介 副主任药师。研究方向:治疗药物监测及药学信息。电话:025—83304616—66662。E—mail:gyyptx@yahoo.com.cn 通讯作者:主任药师。研究方向:医院药学。电话:025-83304616-66660
  • 相关文献

参考文献10

二级参考文献39

  • 1金惠敏,沈清瑞,吴培根,尹培达,张仕光,纪玉莲,郑克立,戴宇平,陈凌武.肾移植术后监测CsA谷浓度的临床价值[J].中华肾脏病杂志,1994,10(3):148-151. 被引量:9
  • 2郭平,李芚,廖工铁.环孢菌素临床药代动力学研究进展[J].中国药学杂志,1995,30(10):585-588. 被引量:19
  • 3Belitsky P,Levy GA,Johnston A.Neoral absorption profiling:an evolution in effectiveness[J].Transplant Proc,2000,32(suppl3A):45S.
  • 4[1]Sullivan KM.Graft-versus-host disease[A].In: Thomas ED, et al ed.Hematopoietic cell transplantation[M].2nd ed.Malden:Blackwell Science Inc.,1999.515-536.
  • 5[2]Richard AN, Margret SP, Rainer S, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate[J].Blood, 1992, 80(12): 1838-1845.
  • 6[3]Richard G,Willam EF,Alan W,et al. Cyclosporine monitoring improves graft-versus-host disease prophylaxis after bone marrow transplantation[J].Ann Pharmacother, 1994, 28(6): 379-383.
  • 7[4]Faulds D, Goa KL, Benfield P.Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders[J]. Drugs,1993,45(6):953-1040.
  • 8[1]Cantarovich M, Besner JG, Barkun JS, et al. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy [J]. Clin Transplant, 1998,12(3) :243.
  • 9[4]Kahan BD. Cyclosporine[J]. N Engl J Med, 1989,321(25): 1725.
  • 10[5]Keown PA.New concepts in cyclosporine monitoring[J]. Curr Opin Nephrol Hypertens ,2002,11(6) :619.

共引文献66

同被引文献52

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部